Lactose IR Granules are pharmaceutical excipient granules based on lactose and intended for immediate-release formulation applications. Lactose is a widely used pharmaceutical excipient, particularly as a diluent or filler in oral solid dosage forms. Depending on the material specification, lactose may be supplied as lactose monohydrate, anhydrous lactose, or a defined combination of lactose forms.
The current USP-NF maintains separate monographs for Lactose Monohydrate and Anhydrous Lactose. Lactose Monohydrate is defined as the monohydrate of O-β-D-galactopyranosyl-(1→4)-α-D-glucopyranose, while Anhydrous Lactose is defined as β-lactose or a mixture of β- and α-lactose. Therefore, the exact lactose form should be identified according to the actual product specification.
Lactose IR Granules are a granulated lactose excipient format intended for use in immediate-release pharmaceutical formulations.
The term IR refers to the intended immediate-release application of the finished granule system. It does not represent a separate chemical form of lactose. The underlying lactose remains the specified lactose grade, while the granulated format can provide controlled physical characteristics for pharmaceutical processing.
The performance of an immediate-release formulation depends on the complete formulation, including the active ingredient, lactose grade, other excipients, particle size, moisture, compression conditions and manufacturing process.
Lactose is a carbohydrate excipient commonly used in pharmaceutical formulations. It can provide bulk and act as a diluent or filler in oral solid dosage forms.
Lactose is available in different physical forms. Lactose Monohydrate contains water of crystallization, while Anhydrous Lactose has a different hydration state. USP-NF treats these materials as separate compendial articles.
This distinction is important because hydration state can influence moisture, density, crystallinity and processing behavior.
Immediate-release formulations are designed to release their incorporated active ingredient without an intentional prolonged-release or delayed-release mechanism.
Lactose can serve as a formulation diluent or filler in immediate-release oral solid dosage forms. When supplied in granulated form, its particle characteristics can influence blending, powder handling and manufacturing performance.
However, Lactose IR Granules should not be described as independently guaranteeing a particular dissolution rate. The release performance of the finished formulation depends on the active ingredient, formulation composition, dosage-form design and manufacturing process.
Granulation can provide controlled physical characteristics compared with fine powder materials. Lactose granules can be evaluated for:
These properties can influence powder movement, blending, filling and downstream manufacturing.
Exact numerical values should always be taken from the approved product specification or certificate of analysis.
Particle-size distribution is an important characteristic of granulated lactose. Depending on the intended application, the specification may include sieve-size distribution or D10, D50 and D90 values.
A controlled particle-size distribution can support consistent powder handling and blending. Granule morphology can also influence bulk density, packing and flow.
For Lactose IR Granules, the actual particle-size specification should be based on the commercial grade rather than applying a generic industry range.
Bulk density and tapped density are useful physical characteristics for evaluating pharmaceutical excipients.
For granulated lactose, these properties can influence material handling, hopper filling, powder transfer and blending behavior. Flow properties can also affect consistency during pharmaceutical manufacturing.
Where available, the SDP product specification can include bulk density, tapped density, Carr index, Hausner ratio or another validated flow measurement.
These values are grade-specific and should not be invented.
The exact lactose form should be clearly identified for the commercial product.
USP-NF currently recognizes Lactose Monohydrate and Anhydrous Lactose as separate materials. (doi.usp.org)
Lactose Monohydrate has the molecular formula C₁₂H₂₂O₁₁·H₂O and a molecular weight of approximately 360.32 g/mol. Anhydrous lactose has the molecular formula C₁₂H₂₂O₁₁ and a molecular weight of approximately 342.30 g/mol.
FCC describes lactose as a white to creamy-white crystalline material and states that it may be anhydrous, contain one molecule of water of hydration, or contain a mixture of both forms depending on how it is prepared. FCC also describes lactose as soluble in water, very slightly soluble in alcohol and insoluble in chloroform and ether. (doi.usp.org)
Lactose IR Granules can be evaluated for use in tablets, capsules and other oral solid dosage forms where a lactose excipient is appropriate.
The granulated material can provide a controlled particle format for formulation development. The suitability of the product depends on its particle size, density, moisture, flow properties and compatibility with the other formulation ingredients.
For tablet formulations, the final product may additionally be evaluated for hardness, friability, disintegration and dissolution.
Moisture control is particularly important when working with different lactose forms.
Lactose Monohydrate has a defined water of crystallization, whereas Anhydrous Lactose represents a different physical and chemical form. USP-NF maintains separate monographs for these materials.
Therefore, the CMS fields for Loss on Drying and Water Content should not automatically contain the same value.
The applicable moisture specification should be taken from the actual product form and approved certificate of analysis.
Pharmaceutical-grade Lactose IR Granules can be evaluated for identity, lactose content, moisture, residue on ignition, optical rotation, particle-size distribution and microbial quality, as applicable to the selected lactose form and pharmacopoeial standard.
The applicable requirements depend on whether the material is Lactose Monohydrate, Anhydrous Lactose or another defined lactose grade.
Where USP/NF compliance is claimed, the actual product should comply with the current applicable USP-NF monograph.
During formulation development, Lactose IR Granules can be evaluated for particle size, density, flow, moisture, compressibility and compatibility with other formulation components.
The final release performance of an immediate-release formulation should be established through appropriate formulation development and dissolution testing.
The term IR should therefore be used to describe the intended finished-product application and not as a substitute for a product-specific dissolution specification.
Lactose IR Granules can be considered for:
The final application depends on the selected lactose form, grade and formulation requirements.
The finished Lactose IR Granules should be tested against the applicable product specification.
Important characteristics may include identification, lactose content, moisture, loss on drying, residue on ignition, specific optical rotation, particle-size distribution and microbial quality.
For the finished granule grade, physical properties such as D10, D50, D90, bulk density, tapped density and flow should be stated only when supported by the actual product specification or CoA.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 0.5% |